Cytokinetics at present launched optimistic outcomes from Sequoia-HCM, its Section 3 scientific trial of the experimental drug aficamten in sufferers with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Sufferers handled with aficamten confirmed considerably elevated train capability as demonstrated by a 1.74 level improve in peak oxygen uptake (pVO2) measured throughout cardiopulmonary train testing. Enhancements have been additionally seen in provoked outflow tract gradients, and most significantly, sufferers felt higher.
The examine had enrollment of roughly 300 sufferers who have been adopted for twenty-four weeks.
Aficamten was well-tolerated, adversarial occasions have been similar to these taking a placebo, and importantly, there have been no situations of worsening coronary heart failure or remedy interruptions attributable to low left ventricular ejection fraction (LVEF).
Based on an article in Med Metropolis Information, the drug could have a bonus over the Bristol Myers Squibb drug mavacamten (offered underneath the model identify Camzyos) as a result of there have been no experiences of worsening coronary heart failure. Within the Section 3 EXPLORER trial of mavacamten, seven sufferers within the remedy group skilled reductions to their LVEF.
Primarily based on the projected success of aficamten, Cytokinetics inventory worth jumped by 83% and the corporate is alleged to be the topic of takeover curiosity from AstraZeneca and Novartis.
Cytokinetics plans to use for FDA approval for the drug within the second half of 2024.
Full outcomes from SEQUOIA-HCM can be introduced at an upcoming medical convention.
You may learn extra in regards to the drug in these earlier articles on HCMBeat:
Cytokinetics Teases Upcoming Section 3 Aficamten Trial in nHCM
Promising Knowledge about Aficamten Offered at Conferences
Aficamten Updates from Cytokinetics
Extra on Aficamten & Mavacamten from ACC 2022
Aficamten Will get “Breakthrough Drug” Standing from FDA
Cytokinetic’s Drug Aficamten & Upcoming HCM Summit – Interview with Dr. Martin Maron
Outcomes Revealed from REDWOOD-HCM Section 2 Trial
The Way forward for HCM Therapy